Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1996 to 2010 of 8314 results

  1. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes, (MT740)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  2. Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy, (MT158)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  3. Jada, (MT826)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. Urolon, (MT821)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  5. BPMpathway for rehabilitation support in joint replacement surgery, (MIB319)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  7. iQoro neuromuscular training device, (MT809)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Spectra Optia for plasma exchange, (MT828)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  9. Electrosurgery (diathermy and coblation) for tonsillectomy, (IP324/2)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  10. Accuro handheld ultrasound device for locating intervertebral space for administration of spinal anaesthesia

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  11. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MT434

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  12. Differential Target Multiplexed Spinal Cord Stimulation (MT742)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  13. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development